Alberto Berman

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Michael Schiff, M. Keiserman, C. Codding et al. · Annals of the Rheumatic Diseases · 2007 · 536 citations · Full text

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo‐controlled trial

René Westhovens, David E. Yocum, John Han et al. · Arthritis & Rheumatism · 2006 · 311 citations

Pharmacotherapy, Inflammatory Arthritis, Inflammation +20

Rheumatic manifestations of human immunodeficiency virus infection

Alberto Berman, Luis R. Espinoza, Joseph D. Diaz et al. · The American Journal of Medicine · 1988 · 284 citations

Primary Immunodeficiency, Rheumatology, Human Retrovirus +7

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8